S&P 500   3,627.04 (-0.31%)
DOW   29,672.57 (-0.80%)
QQQ   299.40 (+0.13%)
AAPL   117.21 (+0.53%)
MSFT   214.79 (-0.20%)
FB   276.49 (-0.48%)
GOOGL   1,782.55 (-0.25%)
AMZN   3,202.20 (+0.21%)
TSLA   601.00 (+2.60%)
NVDA   530.45 (+0.00%)
BABA   268.45 (-2.90%)
CGC   28.95 (-0.17%)
GE   10.41 (+0.10%)
MU   64.31 (+0.12%)
AMD   87.47 (+0.32%)
T   28.95 (-0.28%)
NIO   53.73 (-0.50%)
F   9.23 (+1.54%)
ACB   11.14 (+6.40%)
NFLX   489.65 (-0.35%)
BA   216.13 (-0.17%)
GILD   59.75 (-0.47%)
DIS   146.77 (-0.24%)
S&P 500   3,627.04 (-0.31%)
DOW   29,672.57 (-0.80%)
QQQ   299.40 (+0.13%)
AAPL   117.21 (+0.53%)
MSFT   214.79 (-0.20%)
FB   276.49 (-0.48%)
GOOGL   1,782.55 (-0.25%)
AMZN   3,202.20 (+0.21%)
TSLA   601.00 (+2.60%)
NVDA   530.45 (+0.00%)
BABA   268.45 (-2.90%)
CGC   28.95 (-0.17%)
GE   10.41 (+0.10%)
MU   64.31 (+0.12%)
AMD   87.47 (+0.32%)
T   28.95 (-0.28%)
NIO   53.73 (-0.50%)
F   9.23 (+1.54%)
ACB   11.14 (+6.40%)
NFLX   489.65 (-0.35%)
BA   216.13 (-0.17%)
GILD   59.75 (-0.47%)
DIS   146.77 (-0.24%)
S&P 500   3,627.04 (-0.31%)
DOW   29,672.57 (-0.80%)
QQQ   299.40 (+0.13%)
AAPL   117.21 (+0.53%)
MSFT   214.79 (-0.20%)
FB   276.49 (-0.48%)
GOOGL   1,782.55 (-0.25%)
AMZN   3,202.20 (+0.21%)
TSLA   601.00 (+2.60%)
NVDA   530.45 (+0.00%)
BABA   268.45 (-2.90%)
CGC   28.95 (-0.17%)
GE   10.41 (+0.10%)
MU   64.31 (+0.12%)
AMD   87.47 (+0.32%)
T   28.95 (-0.28%)
NIO   53.73 (-0.50%)
F   9.23 (+1.54%)
ACB   11.14 (+6.40%)
NFLX   489.65 (-0.35%)
BA   216.13 (-0.17%)
GILD   59.75 (-0.47%)
DIS   146.77 (-0.24%)
S&P 500   3,627.04 (-0.31%)
DOW   29,672.57 (-0.80%)
QQQ   299.40 (+0.13%)
AAPL   117.21 (+0.53%)
MSFT   214.79 (-0.20%)
FB   276.49 (-0.48%)
GOOGL   1,782.55 (-0.25%)
AMZN   3,202.20 (+0.21%)
TSLA   601.00 (+2.60%)
NVDA   530.45 (+0.00%)
BABA   268.45 (-2.90%)
CGC   28.95 (-0.17%)
GE   10.41 (+0.10%)
MU   64.31 (+0.12%)
AMD   87.47 (+0.32%)
T   28.95 (-0.28%)
NIO   53.73 (-0.50%)
F   9.23 (+1.54%)
ACB   11.14 (+6.40%)
NFLX   489.65 (-0.35%)
BA   216.13 (-0.17%)
GILD   59.75 (-0.47%)
DIS   146.77 (-0.24%)
Log in
TSE:GUD

Knight Therapeutics Inc. (GUD.TO) Stock Forecast, Price & News

C$5.52
-0.03 (-0.54 %)
(As of 11/27/2020 05:41 PM ET)
Add
Compare
Today's Range
C$5.39
Now: C$5.52
C$5.59
50-Day Range
C$5.32
MA: C$5.53
C$5.76
52-Week Range
C$4.73
Now: C$5.52
C$8.12
Volume413,058 shs
Average Volume313,039 shs
Market CapitalizationC$722.78 million
P/E Ratio27.74
Dividend YieldN/A
BetaN/A
Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; Mytesi for symptomatic relief of noninfectious diarrhea in adult patients with HIV or AIDS on ART; NERLYNX for the treatment of HER2-positive breast cancer; and Trelstar for prostate cancer. It also develops Probuphine to treat opioid addiction; NeurAxon family for acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; NeurAxon family for acute migraine, pain and neurological disorders; AzaSite for bacterial conjunctivitis; Iluvien to treat diabetic macular edema; Netildex for ocular inflammation; 60P family to tre Ibsrela at tropical diseases; Advaxis family to treat HPV-associated cancers and others; Triumvira family, a novel T-cell therapies for cancer; Burinex for the treatment of edema associated with congestive heart failure, cirrhosis of the liver and renal disease; Impavido, an oral drug treatment based on miltefosine for the visceral, cutaneous, and mucocutaneous leishmaniasis; and Imvexxy for moderate-to-severe dyspareunia and Bijuva for moderate-to-severe vasomotor symptoms due to menopause. It develops FLEXISEQ for pain and joint stiffness associated with osteoarthritis; Crescita family dermo-cosmetic line of products; Arakoda, a prevention of malaria; and Tenapanor for hyperphosphatemia treatment. It develops TULSA-PRO, a medical device for prostate ablation. It finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
Read More
Knight Therapeutics Inc. (GUD.TO) logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone514-484-4483
Employees27

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$181.60 million
Cash FlowC$3.12 per share
Book ValueC$6.77 per share

Profitability

Miscellaneous

Market CapC$722.78 million
Next Earnings Date3/29/2021 (Estimated)
OptionableNot Optionable
C$5.52
-0.03 (-0.54 %)
(As of 11/27/2020 05:41 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GUD News and Ratings via Email

Sign-up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Knight Therapeutics Inc. (GUD.TO) (TSE:GUD) Frequently Asked Questions

How has Knight Therapeutics Inc. (GUD.TO)'s stock been impacted by COVID-19?

Knight Therapeutics Inc. (GUD.TO)'s stock was trading at C$6.04 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GUD stock has decreased by 8.6% and is now trading at C$5.52.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Knight Therapeutics Inc. (GUD.TO)?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics Inc. (GUD.TO) in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Knight Therapeutics Inc. (GUD.TO)
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Knight Therapeutics Inc. (GUD.TO)?

Wall Street analysts have given Knight Therapeutics Inc. (GUD.TO) a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Knight Therapeutics Inc. (GUD.TO) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Knight Therapeutics Inc. (GUD.TO)'s next earnings date?

Knight Therapeutics Inc. (GUD.TO) is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021.
View our earnings forecast for Knight Therapeutics Inc. (GUD.TO)
.

What price target have analysts set for GUD?

4 Wall Street analysts have issued 1-year price objectives for Knight Therapeutics Inc. (GUD.TO)'s stock. Their forecasts range from C$6.75 to C$8.00. On average, they anticipate Knight Therapeutics Inc. (GUD.TO)'s share price to reach C$7.56 in the next year. This suggests a possible upside of 37.0% from the stock's current price.
View analysts' price targets for Knight Therapeutics Inc. (GUD.TO)
.

Who are some of Knight Therapeutics Inc. (GUD.TO)'s key competitors?

What other stocks do shareholders of Knight Therapeutics Inc. (GUD.TO) own?

Who are Knight Therapeutics Inc. (GUD.TO)'s key executives?

Knight Therapeutics Inc. (GUD.TO)'s management team includes the following people:
  • Mr. Jonathan Ross Goodman B.A., L.L.B., M.B.A., BA, LLB, MBA, Founder, CEO & Director (Age 51, Pay $607.95k)
  • Ms. Samira Sakhia B.Com., C.P.A., M.B.A., MBA, BCom, CPA, DPA, CA, Pres & Director (Age 52, Pay $616.21k)
  • Mr. Arvind Utchanah, Chief Financial Officer
  • Ms. Amal Khouri M.B.A., VP of Bus. Devel.
  • Ms. Jody Engel, Director of Bus. Devel.
  • Mr. Michel Loustric, Pres of Knight Barbados

What is Knight Therapeutics Inc. (GUD.TO)'s stock symbol?

Knight Therapeutics Inc. (GUD.TO) trades on the Toronto Stock Exchange (TSX) under the ticker symbol "GUD."

How do I buy shares of Knight Therapeutics Inc. (GUD.TO)?

Shares of GUD and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Knight Therapeutics Inc. (GUD.TO)'s stock price today?

One share of GUD stock can currently be purchased for approximately C$5.52.

How big of a company is Knight Therapeutics Inc. (GUD.TO)?

Knight Therapeutics Inc. (GUD.TO) has a market capitalization of C$722.78 million and generates C$181.60 million in revenue each year. Knight Therapeutics Inc. (GUD.TO) employs 27 workers across the globe.

What is Knight Therapeutics Inc. (GUD.TO)'s official website?

The official website for Knight Therapeutics Inc. (GUD.TO) is www.gud-knight.com.

How can I contact Knight Therapeutics Inc. (GUD.TO)?

The company can be reached via phone at 514-484-4483.

This page was last updated on 11/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.